We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener

Session Item

Poster Presentation: Prostate
Poster presentation
World Congress of Brachytherapy 2021
HDR Brachytherapy Monotherapy in patients with Low/Intermediate-risk Prostate Cancer
PP-0159

Abstract

HDR Brachytherapy Monotherapy in patients with Low/Intermediate-risk Prostate Cancer
Authors:

ELENA MORENO OLMEDO1, GORKA NAGORE2, VLADIMIR SUÁREZ-GIRONZINI1, CRISTINA MINGUEZ3, EMILIA GÓMEZ4, ALBERTO GARCIA5, VIOLETA CIAPA6, INMACOLATA MARRONE1, ESCARLATA LÓPEZ1

1GenesisCare Spain, Radiation Oncology, Vithas La Milagrosa Hospital, MADRID, Spain; 2GenesisCare Spain, Radiation Oncology, Vithas Alicante Hospital, ALICANTE, Spain; 3GenesisCare Spain, Radiophysics, Vithas La Milagrosa Hospital, MADRID, Spain; 4GenesisCare Spain, Radiophysics, Vithas Alicante Hospital, ALICANTE, Spain; 5Genesiscare Spain, Radiophysics, Vithas Alicante Hospital, ALICANTE, Spain; 6Genesiscare Spain, Radiation Oncology Nurse, Vithas La Milagrosa Hospital, MADRID, Spain

Show Affiliations
Purpose or Objective

To evaluate the feasibility and toxicity of high-dose-rate (HDR)-brachytherapy (BT) as monotherapy in a prospective clinical trial consisting in two sessions interval 6 hours of a single implant for localized prostate cancer. We report the Acute and Chronic Genitourinary (GU) and Gastrointestinal Toxicity (GI) and Disease Control.

Material and Methods

Between November 2010 and October 2020 a total of 119 patients were treated.  The prescribed dose was 27 Gy in 2 fractions in a day using a single implant. 24 patients (20.1%) was Intermediate risk cancer. 39 patients (33%) received hormonal therapy. Biochemical prostate-specific antigen (PSA) failure was per the Phoenix definition. GU and GI toxicity were evaluated by CTCAE V 4.0. Sexual Function were recorded during follow-up.

Results

Median follow-up was 100 months (range, 33-119). Grade 1-2 acute Toxicity was 26.9%, mainly Frequency/urgency (10%), Dysuria (10%), Dribbling/hesitancy (0.8%). 3 patients required a Foley catheter during 1 week. No acute GI toxicities were recorded. Chronic Genitourinary Toxicities Grade 1-2 were 28.5 %, mainly Dysuria (12.6%), Urinary frequency/urgency (5.8%) and Urinary Incontinence Grade 2 (1.6%); 1 patient had Grade 2 rectal bleeding and 1 patient had Grade 3 GU toxicity requiring RTU. 23.7% of patients without Hormonal therapy reported sexual impotence Grade 1-2 after 2 years therapy. The actuarial Local Control was 99.2%, Biochemical Control 95.8%, Distant Failure 4.2% and Overall Survival was 91.6%.

Conclusion

HDR brachytherapy as monotherapy with longer follow up for localized prostate cancer is an effective treatment with acceptable acute or chronic toxicity. Clinical trials is needed to confirm these encouraging results.